However, lorlatinib received a negative Canadian Health Technology Assessment (HTA) recommendation for the treatment of adult patients with pre-treated ALK-positive metastatic NSCLC owing to the uncertainty of the Phase II non-randomized data [18,19]. Here, ALK is linked to non-small cell lung carcinoma.